Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study
- PMID: 32370577
- PMCID: PMC7212540
- DOI: 10.1080/23744235.2020.1759817
Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study
Abstract
Background: To investigate the risk factors related to aggravation and clinical outcomes in coronavirus disease 2019 (COVID-19) patients.Methods: We performed a retrospective study on the risk factors for disease progression of cases with COVID-19. Based on the clinical types, the patients were divided into a progression group and an improvement group. Multivariable logistic regression and ROC curve analysis were performed to explore the risk factors for disease progression.Results: A total of 101 patients were included in this study; diseases progression occurred in 17 patients, 84 patients improved, 6 were transferred to intensive care unit (ICU), and 5 died. The mean time to obtain negative nucleic acid results was 12.5 ± 5.0 days. Multivariate logistic analysis indicated that age (OR, 0.104; p = .002), C-reactive protein (CRP) (OR, 0.093; p < .001) and lymphocyte count (OR, 3.397; p = .022) were risk factors for disease progression. ROC curve analysis revealed that the AUC of age, CRP and lymphocyte count for disease progression were 0.873, 0.911 and 0.817, respectively.Conclusions: Older age increased CRP and decreased lymphocyte count resulted in potential risk factors for COVID-19 progression. This may be helpful in identifying patients whose condition worsens at an early stage.
Keywords: COVID-19; risk factors outcome.
Figures
Comment in
-
Viral aetiology and clinical characteristics of acute respiratory tract infections in Shenzhen during epidemic of coronavirus disease 2019.Infect Dis (Lond). 2020 Aug;52(8):590-592. doi: 10.1080/23744235.2020.1769855. Epub 2020 May 26. Infect Dis (Lond). 2020. PMID: 32452728 No abstract available.
-
Early experience with COVID-19 patients at academic hospital in Southwestern United States.Infect Dis (Lond). 2020 Aug;52(8):596-599. doi: 10.1080/23744235.2020.1774645. Epub 2020 Jun 1. Infect Dis (Lond). 2020. PMID: 32476537 No abstract available.
-
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity?Infect Dis (Lond). 2020 Aug;52(8):585-589. doi: 10.1080/23744235.2020.1769854. Epub 2020 Jun 1. Infect Dis (Lond). 2020. PMID: 32476551 No abstract available.
-
Tele-rounding in a university hospital pulmonary ward during the COVID-19 pandemic: a pilot study.Infect Dis (Lond). 2020 Sep;52(9):669-670. doi: 10.1080/23744235.2020.1776382. Epub 2020 Jun 9. Infect Dis (Lond). 2020. PMID: 32516031 No abstract available.
-
Laboratory abnormalities related to prolonged hospitalization in COVID-19.Infect Dis (Lond). 2020 Sep;52(9):666-668. doi: 10.1080/23744235.2020.1776381. Epub 2020 Jun 16. Infect Dis (Lond). 2020. PMID: 32543300 No abstract available.
-
Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.Infect Dis (Lond). 2020 Sep;52(9):675-677. doi: 10.1080/23744235.2020.1778178. Epub 2020 Jun 16. Infect Dis (Lond). 2020. PMID: 32543971 No abstract available.
-
Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection.Infect Dis (Lond). 2020 Aug;52(8):600-602. doi: 10.1080/23744235.2020.1772992. Infect Dis (Lond). 2020. PMID: 32552475 No abstract available.
-
A familial cluster of severe coronavirus disease 2019 that required intubation of all family members.Infect Dis (Lond). 2020 Oct;52(10):755-758. doi: 10.1080/23744235.2020.1784999. Epub 2020 Jul 2. Infect Dis (Lond). 2020. PMID: 32615051 No abstract available.
-
Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.Infect Dis (Lond). 2020 Oct;52(10):759-761. doi: 10.1080/23744235.2020.1790031. Epub 2020 Jul 9. Infect Dis (Lond). 2020. PMID: 32643997 No abstract available.
-
Tocilizumab for COVID-19: a real 'miracle drug'?Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17. Infect Dis (Lond). 2020. PMID: 32644027 No abstract available.
-
Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome.Infect Dis (Lond). 2020 Nov;52(11):838-840. doi: 10.1080/23744235.2020.1792544. Epub 2020 Jul 13. Infect Dis (Lond). 2020. PMID: 32657190 No abstract available.
-
Dermatologists may need to pay more attention to herpes zoster during the pandemic of COVID-19.Infect Dis (Lond). 2020 Nov-Dec;52(12):917-918. doi: 10.1080/23744235.2020.1797158. Epub 2020 Jul 22. Infect Dis (Lond). 2020. PMID: 32697129 No abstract available.
-
COVID-19: associated morbidity and mitigation strategies.Infect Dis (Lond). 2020 Nov-Dec;52(12):923-926. doi: 10.1080/23744235.2020.1799071. Epub 2020 Jul 29. Infect Dis (Lond). 2020. PMID: 32726166 No abstract available.
-
Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia.Infect Dis (Lond). 2020 Nov-Dec;52(12):919-922. doi: 10.1080/23744235.2020.1802062. Epub 2020 Aug 11. Infect Dis (Lond). 2020. PMID: 32779951 No abstract available.
-
Preliminary study on relationships among nutritional risk, serum prealbumin, and peripheral blood T cell subsets in patients with severe COVID-19.Infect Dis (Lond). 2021 Jan;53(1):69-71. doi: 10.1080/23744235.2020.1810308. Epub 2020 Aug 31. Infect Dis (Lond). 2021. PMID: 32866084 No abstract available.
-
Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy.Infect Dis (Lond). 2021 Mar;53(3):226-229. doi: 10.1080/23744235.2020.1859131. Epub 2020 Dec 13. Infect Dis (Lond). 2021. PMID: 33307901 No abstract available.
References
-
- WHO main website https://www.who.int [accessed 11 April 2020].
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous